819 related articles for article (PubMed ID: 33593430)
1. Microbiota restoration reduces antibiotic-resistant bacteria gut colonization in patients with recurrent Clostridioides difficile infection from the open-label PUNCH CD study.
Langdon A; Schwartz DJ; Bulow C; Sun X; Hink T; Reske KA; Jones C; Burnham CD; Dubberke ER; Dantas G;
Genome Med; 2021 Feb; 13(1):28. PubMed ID: 33593430
[TBL] [Abstract][Full Text] [Related]
2. Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial.
Kwak S; Choi J; Hink T; Reske KA; Blount K; Jones C; Bost MH; Sun X; Burnham CD; Dubberke ER; Dantas G;
Microbiome; 2020 Aug; 8(1):125. PubMed ID: 32862830
[TBL] [Abstract][Full Text] [Related]
3. The role of the gut microbiome in colonization resistance and recurrent
Seekatz AM; Safdar N; Khanna S
Therap Adv Gastroenterol; 2022; 15():17562848221134396. PubMed ID: 36425405
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
[TBL] [Abstract][Full Text] [Related]
5. Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial.
Orenstein R; Dubberke ER; Khanna S; Lee CH; Yoho D; Johnson S; Hecht G; DuPont HL; Gerding DN; Blount KF; Mische S; Harvey A
BMC Infect Dis; 2022 Mar; 22(1):245. PubMed ID: 35279084
[TBL] [Abstract][Full Text] [Related]
6. Diluted Fecal Community Transplant Restores Clostridioides difficile Colonization Resistance to Antibiotic-Perturbed Murine Communities.
Lesniak NA; Tomkovich S; Henry A; Taylor A; Colovas J; Bishop L; McBride K; Schloss PD
mBio; 2022 Aug; 13(4):e0136422. PubMed ID: 35913161
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal microbiome analysis of single donor fecal microbiota transplantation in patients with recurrent Clostridium difficile infection and/or ulcerative colitis.
Mintz M; Khair S; Grewal S; LaComb JF; Park J; Channer B; Rajapakse R; Bucobo JC; Buscaglia JM; Monzur F; Chawla A; Yang J; Robertson CE; Frank DN; Li E
PLoS One; 2018; 13(1):e0190997. PubMed ID: 29385143
[TBL] [Abstract][Full Text] [Related]
8. Clearance of Clostridioides difficile Colonization Is Associated with Antibiotic-Specific Bacterial Changes.
Lesniak NA; Schubert AM; Sinani H; Schloss PD
mSphere; 2021 May; 6(3):. PubMed ID: 33952668
[TBL] [Abstract][Full Text] [Related]
9. Gram-Negative Taxa and Antimicrobial Susceptibility after Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection.
Steed DB; Wang T; Raheja D; Waldman AD; Babiker A; Dhere T; Kraft CS; Woodworth MH
mSphere; 2020 Oct; 5(5):. PubMed ID: 33055258
[TBL] [Abstract][Full Text] [Related]
10. Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile infection affected by underlying inflammatory bowel disease.
Khanna S; Vazquez-Baeza Y; González A; Weiss S; Schmidt B; Muñiz-Pedrogo DA; Rainey JF; Kammer P; Nelson H; Sadowsky M; Khoruts A; Farrugia SL; Knight R; Pardi DS; Kashyap PC
Microbiome; 2017 May; 5(1):55. PubMed ID: 28506317
[TBL] [Abstract][Full Text] [Related]
11. Recovery of the gut microbiome following fecal microbiota transplantation.
Seekatz AM; Aas J; Gessert CE; Rubin TA; Saman DM; Bakken JS; Young VB
mBio; 2014 Jun; 5(3):e00893-14. PubMed ID: 24939885
[TBL] [Abstract][Full Text] [Related]
12. Long-term beneficial effect of faecal microbiota transplantation on colonisation of multidrug-resistant bacteria and resistome abundance in patients with recurrent Clostridioides difficile infection.
Nooij S; Vendrik KEW; Zwittink RD; Ducarmon QR; Keller JJ; Kuijper EJ; Terveer EM;
Genome Med; 2024 Feb; 16(1):37. PubMed ID: 38419010
[TBL] [Abstract][Full Text] [Related]
13. Does the donor matter? Donor vs patient effects in the outcome of a next-generation microbiota-based drug trial for recurrent Clostridium difficile infection.
Ray A; Jones C
Future Microbiol; 2016 May; 11():611-6. PubMed ID: 26986546
[TBL] [Abstract][Full Text] [Related]
14. Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients.
Fishbein SRS; Hink T; Reske KA; Cass C; Struttmann E; Iqbal ZH; Seiler S; Kwon JH; Burnham CA; Dantas G; Dubberke ER
mSphere; 2021 Jan; 6(1):. PubMed ID: 33441409
[No Abstract] [Full Text] [Related]
15. The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660.
Orenstein R
Infect Dis Ther; 2023 Jan; 12(1):1-7. PubMed ID: 36342653
[TBL] [Abstract][Full Text] [Related]
16. A microbial consortium alters intestinal
Rooney AM; Cochrane K; Fedsin S; Yao S; Anwer S; Dehmiwal S; Hota S; Poutanen S; Allen-Vercoe E; Coburn B;
mBio; 2023 Aug; 14(4):e0348222. PubMed ID: 37404011
[TBL] [Abstract][Full Text] [Related]
17. Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection.
Dubberke ER; Orenstein R; Khanna S; Guthmueller B; Lee C
Infect Dis Ther; 2023 Feb; 12(2):703-709. PubMed ID: 36544075
[TBL] [Abstract][Full Text] [Related]
18. Impact of Amoxicillin-Clavulanate followed by Autologous Fecal Microbiota Transplantation on Fecal Microbiome Structure and Metabolic Potential.
Bulow C; Langdon A; Hink T; Wallace M; Reske KA; Patel S; Sun X; Seiler S; Jones S; Kwon JH; Burnham CA; Dantas G; Dubberke ER
mSphere; 2018 Nov; 3(6):. PubMed ID: 30463925
[TBL] [Abstract][Full Text] [Related]
19. A profile of the live biotherapeutic product RBX2660 and its role in preventing recurrent
Chopra T
Expert Rev Anti Infect Ther; 2023 Mar; 21(3):243-253. PubMed ID: 36756869
[TBL] [Abstract][Full Text] [Related]
20. Randomized clinical trial to evaluate the effect of fecal microbiota transplant for initial Clostridium difficile infection in intestinal microbiome.
Camacho-Ortiz A; Gutiérrez-Delgado EM; Garcia-Mazcorro JF; Mendoza-Olazarán S; Martínez-Meléndez A; Palau-Davila L; Baines SD; Maldonado-Garza H; Garza-González E
PLoS One; 2017; 12(12):e0189768. PubMed ID: 29261736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
